Why don't more patients receive intravenous rt-PA for acute stroke?

Expert Review of Neurotherapeutics

Volumn 15, Issue 6, 2015, Pages 571-574

  Lyden, Patrick ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

cost effectiveness; hemorrhage; stroke; therapy; thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; REVIEW; INTRAVENOUS DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, INTRAVENOUS; FIBRINOLYTIC AGENTS; HUMANS; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84930464554     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1041510     Document Type: Review

References (27)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581-7
2. Report of the Quality Standards Subcommittee of the American Academy of N. Thrombolytic therapy for acute ischemic stroke-Summary Statement. Neurology 1996;47:835
3. Adams HP Jr, Brott TG, et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 1996;94:1167
4. Caplan L, Mohr JP, Kistler JP, Koroshetz W. Should thrombolytic therapy be the first-line treatment for acute ischemic stroke? Thrombolysis-not a panacea for ischemic stroke. New Engl J Med 1997;337:1309
5. Hoffman JR. Thrombolytic therapy for acute ischemic stroke-Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative? Cjem 2001;3(3):183-5
6. Hoffman JR. Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little. Med J Aust 2003;179(7):333-4
7. Mann J. Truths about the NINDS study: setting the record straight. West J Med 2002;176(3):192-4
8. Sinclair SE, Frighetto L, Loewen PS, et al. Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective. Pharmacoeconomics 2001;19(9):927
9. Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology 1998;50:883
10. Group ISTc. Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012, 379, 9834 2352-63
11. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999;340:1781
12. Group Nr-PSS. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Stroke 2000;31:2912
13. Lyden P, Lu M, Kwiatkowski TG, et al. Thrombolysis in patients with transient neurologic deficits. Neurology 2001;57:2125
14. Group Nr-PSS. Generalized Efficacy of t-PA for acute Stroke. Stroke 1997;28:2119
15. Sandercock P, Lindley R, Wardlaw J, et al. Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited. Trials 2011;12(1): 252
16. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-29
17. Sandercock P, Lindley R, Wardlaw J, et al. Third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials 2008;9:37
18. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014; 384(9958):1929-35
19. Clinical Policy: Use of Intravenous tPA for the management of acute ischemic stroke in the emergency department. Ann Emerg Med 2013;61(2):225-43
20. Lenzer J. Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign. BMJ 2002;324(7339):723-9
21. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2006;113(6):e85-151
22. Albright KC, Branas CC, Meyer BC, et al. ACCESS: acute cerebrovascular care in emergency stroke systems. Arch Neurol 2010;67(10):1210-18
23. Tveiten A, Mygland A, Ljostad U, Thomassen L. Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre. Emerg Med J 2009; 26(5):324-6
24. Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med 2010;5(7): 406-9
25. Schwamm LH, Ali SF, Reeves MJ, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes 2013;6(5):543-9
26. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007;38(11):3055-62
27. Davis PH, Torner JC, Holmes J, et al. Lifetime cost of stroke in the United States. Stroke 1996;27:1459.